HR 3 — Reserved for the Speaker.
Congress 119
Sponsors
No sponsorships on file.
Lobbied by (1)
LDA filings that named this bill in their activity descriptions. The lobbying firm (registrant) is paid by the client to lobby on this and related issues.
| Filing | Period | Registrant (lobbying firm) | Client | Income | Matched |
|---|---|---|---|---|---|
| 1st Quarter - Report | 2026 first_quarter | S-3 GROUP | AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. | $60,000 | H.R. 3 |
Action timeline
No actions on file yet — BILLSTATUS ingest fills this for every bill currently in the index. Run npm run db:ingest -- --source=bill-status --congress=119 to pull this bill's actions on demand.
Text versions
No text versions on file yet — same ingest as the action timeline populates these. Each version has direct links to the XML / HTML / PDF at govinfo.gov.
Connected on the graph
Inbound (1)
| date | from | type | amount | role | source |
|---|---|---|---|---|---|
| 2026-01-01 | AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. | lobbies_on_bill | — | H.R. 3 | lobbying_bill_mention |
Who's influencing them
Orgs ranked by combined money flow on this bill: LDA filings citing the bill + individual contributions in cycle 2026from donors whose employer matches the org name (Schedule A) to any principal committee in the "who matters" list above.
| # | Org | LDA filings | LDA spend | Donor employees | Employee donations | Total |
|---|---|---|---|---|---|---|
| 1 | AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. | 1 | $60,000 | 0 | $0 | $60,000 |
Predicted vote
Aggregated from: actual roll-call votes (when present) → sponsor → cosponsor → party median (predicts YES when ≥25% of the caucus sponsored/cosponsored). Each row labels its confidence tier so you can see why a position was predicted.
0 predicted yes (0%) · 543 predicted no (100%) · 0 unknown (0%)
By party: · R: 0 yes / 277 no · D: 0 yes / 263 no · I: 0 yes / 3 no
Activity
Every typed-graph event involving this entity, newest first. Each row is one edge in the influence graph; click the date to jump to its provenance.
- 2026-01-01 · lobbied on by AMGEN, INC. FKA HORIZON THERAPEUTICS USA, INC. (h.r. 3) · lobbying_bill_mention